.
GISTs have a characteristic immuno histochemical profile that is useful for confirming a suspected diagnosis (7) . About 95% are positive for KIT (CD117), 60%
to 70% for CD34, 30% to 40% for smooth muscle actin, 5% for S-100 protein, 1% to 2% for desmin, and 1% to 2% for keratin (8) .
In general, KIT staining in GISTs is strongly and diffusely positive, but it is not necessarily uniform across different regions of the tumor (8) . expression; so-called "KIT-negative GISTs (8) . Metastases can also be found in the soft tissues (such as the abdominal wall) and rarely in the lungs and pleura, bone, or lymph nodes (8) .
Contrast enhanced CT

(B) Assessment of Response:
In the early stages of imatinib therapy, the imatinib than PET-CT (10) .
CT plays an important role in showing tumor stability and identifying any true tumor progression that might signal the clonal emergence of resistance to imatinib. Tumor recurrence after surgical resection can be a metastasis or can occur at the site of primary disease (8) .
CT is performed for surveillance of metastatic or recurrent disease, and
abdominal/pelvic CT scans should be obtained every 3 to 6 months. For very low-risk GISTs, less-frequent follow-up is
appropriate. When progression occurs, imaging frequency should be increased.
Each treated lesion should be carefully analyzed for new intra-tumoral changes.
CT is recommended within 3 months of initiating TKI therapy in patients with definitively un-resectable or metastatic disease (8) . . Choi et al. (12) reported that 80% of lesions show a significant glucose uptake on pretreatment 18F -FDG-PET, hence existence of a baseline 18F-FDG-PET/CT as reference is essential. Consequently, when neo adjuvant imatinib therapy is considered, we believe that a baseline PET/CT is compulsory (12) .This has not been suggested in the NCCN guidelines (8) .
Role of FDG PET/CT in
Initial reports suggest an impressive role 
Complete Metabolic Response (CMR):
Complete resolution of 18F-FDG uptake within measurable target lesion so that it is less than mean liver activity and 
Partial Metabolic Response (PMR):
Reduction of minimum of 30% in target measurable tumor 18F-FDG SUL peak.
Absolute drop in SUL must be at least 0. .
Re-Staging:
For correct re-staging in monitoring the patients, 18FFDG PET/CT has several technological advantages over other diagnostic tests in GIST patients permit to detect small lesions using as a whole body technique which allow the diagnosis of disease in remote locations, Also, the use of integrated PET/CT scanners results in a correct anatomical localization of the hyper metabolic foci, substantially reducing false `17positives (19) .
Results:
Thus, PET/CT allows for maximum 
